Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Meletios A Dimopoulos ,Sonja Zweegman,Agnieszka Pluta,Philippe Moreau,S Vincent Rajkumar,Katja Weisel,Andrew Spencer,Martin Kaiser,Shinsuke Iida,Hartmut Goldschmidt,Ajeeta B Dash,Wee Joo Chng,Zhaoyang Teng,Kaveri Suryanarayan,Richard Labotka,Fredrik Schjesvold ,Gareth J Morgan ,Tomáš Skácel ,Chang‐Ki Min ,Vladimír Maisnar ,Meral Beksaç ,Francesca Gay ,María‐Victoria Mateos ,Roman Hájek

doi:10.1182/blood-2018-99-112079

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Meletios A Dimopoulos , Sonja Zweegman + Show 22 more

Open Access

https://doi.org/10.1182/blood-2018-99-112079

Copy DOI

#Advisory Committees #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Full Text